Koninklijke Philips N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYLPF research report →
Price Chart
About the company
Koninklijke Philips N. V. operates as a leading global healthcare technology enterprise with a presence across North America and numerous international markets.
- CEO
- Roy W. O. Jakobs
- IPO
- 2015
- Employees
- 66,401
- HQ
- Amsterdam, NH, NL
Get TickerSpark's AI analysis on RYLPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.38B
- P/E
- 26.19
- Fwd P/E
- 17.89
- PEG
- 0.05
- P/S
- 1.45
- P/B
- 2.23
- EV/EBITDA
- 9.90
- Div Yield
- 3.22%
- Gross Margin
- 46.43%
- Op Margin
- 10.93%
- Net Margin
- 5.39%
- ROE
- 8.44%
- ROIC
- 6.58%
Latest fiscal year · YoY change
- Revenue
- $17.83B-1.1%
- Gross Profit
- $8.05B+3.6%
- Op Income
- $1.65B
- Net Income
- $895.66M+227.6%
- EPS
- $0.94+225.3%
- OCF Growth
- -25.3%
- FCF Growth
- +1.1%
- 52W High
- $33.00
- 52W Low
- $23.34
- 50D MA
- $26.56
- 200D MA
- $27.43
- Beta
- 0.92
- RSI (14)
- 55
- Avg Volume
- 28.98K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Philips posted broad-based Q3 growth, with stronger-than-expected margins, solid cash generation, and improved order momentum led by Diagnosis & Treatment and Personal Health.· November 3, 2026
- Order intake rose 8% and comparable sales grew about 3%, with margin expansion across all three businesses.
- Adjusted EBITA margin increased 70 bps to 13%; year-to-date underlying margin expansion was 30 bps.
- Free cash flow was EUR 384 million, up from EUR 172 million a year ago, and net debt fell to EUR 5.4 billion.
- Diagnosis & Treatment orders accelerated to nearly 20% growth, while Personal Health sales rose 8% and Connected Care sales grew 5%.
- Philips recorded a EUR 288 million provision tied to a DOJ agreement in principle on Respironics, while reiterating full-year guidance.
Q3 comparable sales grew approximately 3% and order intake increased 8%. Adjusted EBITA margin was 13%, up 70 basis points year over year; adjusted EPS was EUR 0.40, up more than 10% year over year. Free cash flow was EUR 384 million versus EUR 172 million in Q3 last year. Segment-wise, D&T sales were broadly flat, Connected Care sales grew 5%, and Personal Health sales grew 8%. Philips ended Q3 with EUR 2.8 billion in cash and net debt of EUR 5.4 billion, with net debt/adjusted EBITA at 1.7x. For the full year, Philips reiterated comparable sales growth of 3% to 4.5%, adjusted EBITA margin of 13.5% to 14%, and free cash flow of EUR 1.5 billion to EUR 1.7 billion; D&T is expected at the upper end of low single-digit growth, Connected Care in the 3% to 4.5% range, and Personal Health at the lower end of high single-digit growth. Management also said full-year net financial expenses are now expected to be about EUR 230 million.
Roy Jakobs framed the quarter as evidence that Philips is executing well despite inflation, tariffs, and regulatory issues. He emphasized strong order momentum, especially in Diagnosis & Treatment, where he said the order book has been rebuilt and new innovations are gaining traction, and he highlighted continued leadership in Personal Health and Connected Care. His tone was confident and constructive, repeatedly pointing to a positive customer response, AI-enabled innovation, and progress toward the company’s medium-term ambitions.
Charlotte Hanneman focused on margin delivery, cash flow, and balance sheet strength. She said group adjusted EBITA margin reached 13%, year-to-date underlying margin expanded 30 bps to 11.5%, and productivity savings were EUR 170 million in Q3 and EUR 427 million year to date toward the EUR 1.5 billion target by 2028. She also cited a stronger cash position, with EUR 384 million of free cash flow in the quarter, EUR 2.8 billion of cash, net debt of EUR 5.4 billion, and leverage down to 1.7x. She noted the EUR 288 million Respironics DOJ provision, lower expected full-year net financial expenses of about EUR 230 million, and reiterated the full-year outlook.
Analysts focused on whether Philips can sustain margin expansion into 2027, how much of the D&T order strength will convert into sales, and whether Connected Care order timing reflected demand or simply deal slippage. Management said the Q4 margin bridge is still driven by operating leverage, gross margin from innovation, productivity, and a modest tariff benefit, while cautioning that 2027 guidance would come later. On Connected Care, Hanneman said the longer cycle reflects larger, more complex enterprise deals and stressed the company is not losing share, citing large wins and dislodging incumbents. Questions on China and centralized procurement were met with a cautious view: Philips expects pricing pressure to grow and remains prudent on China, while relying on stronger growth in North America, Europe, and other regions to offset it.
The bull case from this call is that Philips is seeing real commercial momentum, not just cost-driven margin gains. Orders are strengthening in D&T, Personal Health is outperforming with market share gains, and Connected Care is increasingly winning large strategic deals with recurring revenue potential. Management also sounded confident that innovation, especially in CT, MR, monitoring, and AI-enabled workflows, is building a base for better growth into 2027 and beyond.
The main risks discussed were China softness, centralized procurement, inflation, tariffs, and timing-related volatility in orders and shipments. D&T sales were still only broadly flat because ultrasound shipments were delayed and China was weaker, and management said some affected sales will spill into Q4 and early 2027. Regulatory and legal overhangs remain as well, including the EUR 288 million Respironics provision and unresolved proceedings beyond the DOJ agreement in principle.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.0%
- Shares Outstanding
- 977.43M
- Float Shares
- 791.92M
Held by 7 ETFs
Biggest fund positions in RYLPF by dollar value.
Our RYLPF coverage
Recent articles, reports, and earnings notes.
No research on RYLPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RYLPF report →Philips: A Risky Turnaround Worth A 'Strong Buy' Upgrade
seekingalpha.com · Oct 19
Koninklijke Philips N.V. (PHG) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.